Pegfilgrastim appears equivalent to daily dosing of filgrastim to treat neutropenia after autologous peripheral blood stem cell transplantation in patients with non-hodgkin lymphoma

Clinical Lymphoma, Myeloma and Leukemia

Volumn 10, Issue 3, 2010, Pages 186-191

  Rifkin, Robert ^a,b   Spitzer, Gary ^a,c   Orloff, Gregory ^a,d   Mandanas, Romeo ^a,e   McGaughey, Dean ^a,f   Zhan, Feng ^a   Boehm, Kristi A ^a   Asmar, Lina ^a   Beveridge, Roy ^a  

^a US Oncology Research Inc   (United States)

^b ROCKY MOUNTAIN CANCER CENTERS   (United States)

^c Cancer Centers of the Carolinas   (United States)

^d Fairfax Northern Virginia Hematology   (United States)

^e Cancer Care Associates   (United States)

^f Virginia Oncology Associates   (United States)

Author keywords

Growth factor; Multicenter; Posttransplantation; Supportive care

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; MELPHALAN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; ANTINEOPLASTIC AGENT; BAEC PROTOCOL; BEAM PROTOCOL; PODOPHYLLOTOXIN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; AUTOLOGOUS PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; BLOOD CULTURE; BONE PAIN; CANCER CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CRYOPRESERVATION; DISEASE DURATION; DRUG MEGADOSE; DYSPNEA; ENGRAFTMENT; ERYTHROCYTE TRANSFUSION; FEBRILE NEUTROPENIA; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; HYPOKALEMIA; HYPOPHOSPHATEMIA; INFECTION; LEUKOCYTE; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUSCULOSKELETAL PAIN; MYALGIA; NEUTROPENIA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; PERIPHERAL BLOOD STEM CELL; PHASE 2 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; CANCER STAGING; LEUKOCYTE COUNT; TREATMENT OUTCOME; AUTOTRANSPLANTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; MIDDLE AGED; MULTICENTER STUDY;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; ETOPOSIDE; FEMALE; FILGRASTIM; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MELPHALAN; MIDDLE AGED; NEOPLASM STAGING; NEUTROPENIA; PODOPHYLLOTOXIN; TRANSPLANTATION, AUTOLOGOUS; YOUNG ADULT;

EID: 77955888016     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.3816/CLML.2010.n.029     Document Type: Article

References (11)

1. Criteria Committee of the New York Heart Association. Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels. 9th ed. Boston, MA: Little, Brown & Co; 1994:253-256
2. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 1982; 5:649-55. Available at: http://ecog.dfci.harvard.edu/general/perf-stat.html. Accessed: April 22, 2009.
3. National Cancer Institute. Common Terminology Criteria for Adverse Events v3.0 (CTCAE), publishing date December 12, 2003. Available at: http://ctep.cancer.gov/forms/CTCAEv3.pdf. Accessed: August 23, 2005.
4. Amgen, Inc. Neulasta (Pegfilgrastim) Prescribing Information. Thousand Oaks, CA: Amgen; 2008.
5. Crawford J. Pegfilgrastim: the promise of pegylation fulfilled. Ann Oncol 2003; 14:6-7.
6. Green MD, Koelbl H, Baselga J, et al. A randomized double-blind multicenter phase III study of fixed dose single-administration pegfilgrastim versus daily filgrastim in patients receiving myelosuppressive chemotherapy. Ann Oncol 2003; 14:29-35.
7. Holmes FA, O'Shaughnessy J, Vukelja S, et al. Blinded, randomized, multicenter study to evaluate single administration pegfilgrastim once per cycle versus daily filgrastim as a adjunct to chemotherapy in patients with high-risk stage II or III/IV breast cancer. J Clin Oncol 2002; 20:727-731
8. Roskos LK, Cheung EN, Vinvent M, et al. Pharmacology of Filgrastim (r-metHuG-CSF). In: Morstyn G, Dexter T, Foote M, eds. Filgrastim (r-metHuG-CSF) in Clinical Practice, 2nd ed. Informa Health Care; 1998:51-71.
9. Valerius T, Elsasser D, Repp R, et al. HLA class-II antibodies recruit G-CSF activated neutrophils for treatment of B-cell malignancies. Leuk Lymphoma 1997; 26:261-269
10. Kaneshiro CA, Chretien SD, Iyer PR. Potential cost savings when switching from filgrastim to pegfilgrastim. J Support Oncol 2004; 2:60.
11. Lyman G, Lalla A, Barron R, et al. Cost-effectiveness of pegfilgrastim verus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States. Curr Med Res Opin 2009; 25:401-411